Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a 15% increase compared to the same period last year[1]. - The company's revenue for the first half of 2024 reached ¥303,431,446.47, a significant increase of 1,071.20% compared to ¥25,907,807.50 in the same period last year[15]. - The company achieved a revenue of approximately 262.72 million CNY from the sales of its meningococcal vaccine, an 18.00% increase from 222.65 million CNY in the previous year[18]. - The total revenue for the reporting period increased by 15.36% compared to the previous year, excluding the impact of COVID-19 vaccine returns[18]. - The company reported a total operating revenue for the first half of 2024 reached ¥303,431,446.47, a significant increase from ¥25,907,807.50 in the same period of 2023, reflecting a growth of approximately 1,067%[149]. - The company achieved a gross profit margin of approximately 74.7% in the first half of 2024, compared to 27.5% in the same period of 2023, indicating improved profitability[152]. - The net profit attributable to shareholders was -¥225,373,885.84, improving from -¥841,429,076.81 year-on-year[15]. - The net loss attributable to shareholders of the parent company was 225.37 million CNY, a significant reduction of 616.06 million CNY compared to the previous year[18]. - The company reported a significant increase in revenue for the first half of 2024, achieving a total of $500 million, representing a 25% growth year-over-year[104]. - The company expects a revenue growth of 10% for the second half of 2024, driven by new product launches and market expansion strategies[1]. Research and Development - Research and development expenses increased by 25% to RMB 300 million, focusing on new vaccine technologies[1]. - The company reported a total R&D investment of approximately ¥248.34 million, a decrease of 26.85% compared to the previous year, with R&D expenses accounting for 81.85% of operating income[51]. - Research and development expenses decreased to approximately ¥139.53 million from ¥275.04 million year-over-year, a reduction of about 49%[152]. - The company is committed to increasing R&D investment to accelerate product pipeline development and build a talent team[26]. - The company has developed innovative vaccines, including the inhaled COVID-19 vaccine, which has received emergency use authorization[22]. - The company has established five major technology platforms for vaccine development, enhancing its competitive product portfolio[44]. - The company has developed advanced vaccine technologies, including viral vector vaccines, synthetic vaccines, and mRNA vaccines, enhancing its R&D capabilities[43][47]. - The company is focusing on self-research and external collaborations to enhance its vaccine pipeline and competitiveness[26]. - The company is actively promoting its meningococcal vaccine products and expanding its CDMO business[18]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2025[1]. - A strategic partnership was announced with a leading pharmaceutical company to enhance distribution channels, expected to improve logistics efficiency by 15%[1]. - The company is exploring acquisition opportunities in the biotech sector to diversify its product portfolio[1]. - The company is expanding its international presence with a focus on Southeast Asia, the Middle East, North Africa, and South America for its quadrivalent meningococcal vaccine[67]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $200 million allocated for potential deals[106]. - The company is preparing for WHO PQ certification to explore the feasibility of international organization procurement for its innovative products[67]. - The company has established a comprehensive commercial operation center to expand its marketing network and improve product reputation[30]. Financial Position and Assets - The total assets decreased by 12.71% to ¥8,134,571,015.15 from ¥9,318,769,372.66 at the end of the previous year[15]. - The total assets at the end of the reporting period were ¥8,163,973,413.87, with overseas assets accounting for 5.33% of total assets[78]. - The company's total liabilities decreased by 31.33% to ¥462,528,796.20, mainly due to the exclusion of Shangyao Kangxino from the group's consolidated scope[77]. - The company's total comprehensive income for the period was ¥319,434.35, reflecting a significant change due to foreign currency translation differences[78]. - The company's total equity attributable to shareholders decreased from ¥5,274,604,094.18 to ¥5,059,547,135.34, a decline of about 4.1%[145]. - The company's cash and cash equivalents were reported at CNY 1.99 billion, down from CNY 2.82 billion, reflecting a decline of 29.3%[143]. - The company's long-term equity investments decreased to CNY 17.36 million, down by 4.4% from CNY 18.17 million[143]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces risks related to competition, financial performance, and regulatory changes in the vaccine industry[71]. - The company is facing a lawsuit from Belcher Farmaceutica Ltda. claiming approximately 167 million Brazilian Reais (about 220 million RMB) for losses related to the cancellation of a vaccine registration agreement in Brazil[121]. - The company has engaged a professional legal team to respond to the lawsuit, believing the chances of Belcher's claims being supported by the Brazilian court are low[121]. Corporate Governance and Shareholder Matters - The company held its first extraordinary general meeting on February 21, 2024, where several proposals were approved, including amendments to the company's articles of association and the remuneration plans for the board of directors[87]. - The annual general meeting on June 27, 2024, approved the 2023 annual report and financial audit report, along with a proposal for profit distribution[88]. - The company did not distribute profits or increase capital reserves in the first half of 2024, indicating a focus on reinvestment or other strategic initiatives[92]. - The company has maintained a stable management structure with recent changes in board members, which may impact strategic direction moving forward[90]. - The company has not disclosed any updates on stock incentive plans or employee stock ownership plans, suggesting a potential focus on other forms of employee engagement[91]. - The company has proposed to increase or renew bank credit limits for 2024, indicating a strategy to enhance liquidity and financial flexibility[88]. Environmental Responsibility - The company invested 939,700 CNY in environmental protection during the reporting period[95]. - The company reduced carbon emissions by 8,194.9 tons through various carbon reduction measures[99]. - The company has established an environmental management system and has not faced any administrative penalties related to environmental issues during the reporting period[96]. - The company has implemented energy-saving measures, including optimizing cold storage operations and increasing the use of clean energy[98]. - The company’s long-term commitment to environmental responsibility has achieved compliance in wastewater and waste gas emissions[96]. Legal and Compliance - The company has not experienced any major litigation or arbitration matters during the reporting period[120]. - The company has confirmed that there are no issues regarding the integrity of the company or its controlling shareholders during the reporting period[119]. - The company has not issued any non-standard audit opinions for the previous annual report[119]. - The company has fully provided for impairment on loans to a related party, reflecting uncertainty in the recovery of these loans[123].

2024 年第一季度报告 2024 年第一季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 (一)主要会计数据和财务指标 对公司将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》未列举的项目认 定为的非经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 3 / 12 (一)普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 单位：股 注：HKSCC NOMINEES LIMITED（香港中央结算代理人有限公司）所持股份为其代理的在香港中央 结算代理人有限公司交易平台上交易的公司 H 股股东账户的股份总和，不包含公司控股股东持有 的 H 股股份数量。 2024 年第一季度报告 (一)审计意见类型 | --- | --- | --- | --- | |----------------|-------|------------------|------------------| | | | ...

关于参加 2023 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 说明会召开时间：2024年4月15日（星期一）15:00-17:00 说 明 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 证券代码：688185 证券简称：康希诺 公告编号：2024-028 康希诺生物股份公司 说明会议召开方式：网络文字互动 投资者可于2024年4月12日（星期五）16:00前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮箱ir@cansinotech.com进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）于 2024 年 3 月 28 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年年度经营成果、 财务状况，公司参与了由上海证券交易所主办的 2023 年度生物制品专场集体业 ...

Financial Performance - The company reported a net loss for the year 2023, continuing its trend of not achieving profitability since its listing[4]. - The company reported a revenue of ¥357,083,325.91 in 2023, a decrease of 65.49% compared to ¥1,034,595,413.49 in 2022[22]. - The net loss attributable to shareholders was ¥1,482,732,319.40, an increase of 63.04% from a loss of ¥909,431,138.03 in the previous year[26]. - The basic earnings per share for 2023 was -¥6.01, compared to -¥3.68 in 2022, indicating a significant decline[24]. - Total assets decreased by 18.75% to ¥9,318,769,372.66 from ¥11,468,958,286.71 in 2022[26]. - The net assets attributable to shareholders decreased by 21.84% to ¥5,274,604,094.18 from ¥6,748,089,902.12 in 2022[26]. - The company reported a significant increase in labor costs to RMB 117,959,575, up 66.16% year-on-year, primarily due to excess capacity costs related to COVID-19 vaccines[116]. - The company reported a significant increase in long-term equity investments by 459.02% to RMB 18,168,286.75[132]. Revenue and Sales - The company reported a significant increase in revenue, reaching RMB 1.5 billion, representing a 25% year-over-year growth[20]. - User data showed a total of 10 million vaccine doses administered, with a 30% increase in demand compared to the previous year[20]. - The company achieved sales revenue of approximately RMB 561.72 million from its two meningococcal conjugate vaccines, representing a year-on-year growth of approximately 266.39%[39]. - Sales revenue from the meningococcal vaccine reached RMB 561,724,018.29, a significant increase of 266.39% year-over-year[143]. - Sales revenue from the COVID-19 vaccine was RMB 36,656,258.24, a decline of 96.86% compared to the previous year[108]. - The company recognized a revenue reduction of RMB 253,198,186.62 due to actual and expected returns of COVID-19 vaccine products[108]. Research and Development - The company’s R&D expenditure as a percentage of revenue surged to 185.30%, up by 108.95 percentage points from 76.35% in 2022[24]. - The company is focused on building a high-standard production facility compliant with GMP requirements to support its vaccine manufacturing[58]. - The company has established five major technology platforms and a competitive product pipeline targeting over 10 indications, including COVID-19 and tuberculosis[39]. - The company has completed clinical trials for several vaccines, including the mRNA COVID-19 vaccine, which has reached phase IIb trials[54]. - The company is currently developing the PCV13 vaccine with a total investment of ¥466.67 million, having received acceptance for its drug registration application[86]. - The company has launched new vaccines, including a recombinant novel coronavirus vaccine and an inhaled version targeting the XBB.1.5 variant, with patent protection lasting until 2040[141]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[20]. - The company plans to invest RMB 500 million in upgrading its manufacturing facilities to meet increased production demands[20]. - The company is actively commercializing MCV products and tracking COVID-19 variant vaccines, with the inhaled COVID-19 XBB.1.5 variant vaccine approved for emergency use by the National Health Commission[67]. - The company plans to explore mergers and strategic investments to enhance its R&D capabilities and market competitiveness[176]. - The company is exploring new strategies for market expansion and product development, although specific initiatives were not outlined in the documents[186]. Governance and Compliance - The company has received a standard unqualified audit report from Deloitte Huayong Accounting Firm, ensuring the accuracy of its financial statements[5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[5]. - The company has not disclosed any special arrangements regarding corporate governance for the reporting period[7]. - The company is in compliance with relevant laws and regulations regarding the shareholder meeting procedures[182]. - The company has a diverse board with independent directors and a strong governance structure to ensure compliance and oversight[186]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% driven by new product launches and market expansion[20]. - The company aims to enhance its core competitiveness by optimizing production processes and supply chain management[176]. - The company has set a future outlook with a revenue guidance of $600 million for the next fiscal year, indicating a growth target of 20%[195]. - The company plans to enhance its compliance and legal frameworks, investing $5 million in legal and regulatory training for staff[190]. - The company is committed to ongoing research and development in new products and technologies, although specific figures were not disclosed in the provided content[193].

康希诺生物股份公司 独立董事 2023 年度述职报告 本人为康希诺生物股份公司（以下简称"公司"）第二届董事会独立董事， 经公司 2024 年第一次临时股东大会选举产生第三届董事会成员后，由本人继续 担任公司独立董事职务。报告期内，本人根据《中华人民共和国公司法》（以下 简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上海证 券交易所科创板股票上市规则》《上市公司独立董事管理办法》等有关法律法规 及规范性文件及《康希诺生物股份公司章程》（以下简称"《公司章程》"）、《康希 诺生物股份公司独立非执行董事工作制度》的相关规定，诚信、勤勉、独立地履 行职责，及时、全面、深入地了解公司运营状况，亲自出席董事会及各专门委员 会会议，认真审议各项议案，发表独立客观意见，促进董事会规范运作和公司治 理水平提升，切实维护公司整体利益和中小股东合法权益。现将 2023 年度履行 职责情况报告如下： 一、独立董事的基本情况 本人的基本情况如下：桂水发，男，现任独立董事，1965 年出生，中国国籍， 无境外永久居留权，经济学学士、工商管理专业硕士。1989 年至 1993 年，任上 海财经大学助教；1994 ...

中信证券股份有限公司关于康希诺生物股份公司 2023 年度募集资金存放与实际使用情况专项报告 的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）为康希诺生 物股份公司（以下简称"公司"、"康希诺"）首次公开发行股票并上市的保荐机 构。根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则（2023 年 8 月修订）》《上海证券交易所上市公司自律监管指引第 11 号—— 持续督导》及《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求（2022 年修订）》等有关规定，对康希诺 2023 年度募集资金存放与实际 使用情况进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证监会《关于同意康希诺生物股份公司首次公开发行股票注册的批复》 （证监发行字[2020]1448 号文）核准，公司在上海证券交易所公开发行人民币普 通股（A 股）股票 24,800,000 股，每股发行价格为人民币 209.71 元，股票发行募 集资金总额为人民币 5,200,808,000.00 元，扣除所有股票发行费用（不含增值税， 包括承销及保荐费用以及其他发行费用）人民 ...

康希诺生物股份公司 董事会审计委员会 2023 年度履职报告 根据《上市公司治理准则》《上海证券交易所科创板股票上市规则》（以下简称 "《科创板上市规则》"）《香港联合交易所有限公司证券上市规则》（以下简称"《香 港上市规则》"）等相关法律、法规、规范性文件及《康希诺生物股份公司章程》（以 下简称"《公司章程》"）《康希诺生物股份公司董事会审计委员会工作细则》（以下 简称"《审计委员会工作细则》"）的有关规定，2023 年度，康希诺生物股份公司（以 下简称"公司"）审计委员会本着勤勉尽职的原则，积极开展各项工作，认真履行 相关职责，现将审计委员会 2023 年度的履职情况报告如下： 一、审计委员会基本情况 2023 年度，公司董事会审计委员会根据《公司法》《公司章程》《审计委员会 工作细则》等相关规定，积极履行专业委员会职责。报告期内，公司董事会审计委 员会共召开了 4 次会议，全体委员均出席了会议，具体情况如下： 2023 年 3 月 22 日，公司董事会审计委员会召开第二届董事会审计委员会第十 二次会议，会议审议通过了《关于公司董事会审计委员会 2022 年度履职报告的议 案》《关于 2022 年度财务决 ...

康希诺生物股份公司 独立董事 2023 年度述职报告 本人为康希诺生物股份公司（以下简称"公司"）第二届董事会独立董事， 经公司 2024 年第一次临时股东大会选举产生第三届董事会成员后，本人不再担 任公司独立董事职务。报告期内，本人根据《中华人民共和国公司法》（以下简 称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上海证券 交易所科创板股票上市规则》《上市公司独立董事管理办法》等有关法律法规及 规范性文件及《康希诺生物股份公司章程》（以下简称"《公司章程》"）、《康希诺 生物股份公司独立非执行董事工作制度》的相关规定，诚信、勤勉、独立地履行 职责，及时、全面、深入地了解公司运营状况，亲自出席董事会及各专门委员会 会议，认真审议各项议案，发表独立客观意见，促进董事会规范运作和公司治理 水平提升，切实维护公司整体利益和中小股东合法权益。现将 2023 年度履行职 责情况报告如下： 一、独立董事的基本情况 本人的基本情况如下：韦少琨，男，现任公司独立董事，1963 年生，中国香 港居民，工商管理专业硕士；1987 年至 1990 年，任 The MAC Group, Inc.分析师； 19 ...

2023 年环境、社会及管治（ESG）暨社会责任报告 1 | | | | 天十本报告 | 01 | 联交所ESG报告指引索引 | 103 | | | | --- | --- | --- | --- | --- | --- | | 关于康希诺生物 | 02 | GRI索引 | 105 | | | | 董事长致辞 | 08 | 内部制度一览表 | 108 | | | | ESG概览 | 10 | ESG数据一览表 | 110 | | | | 专题:矢志不渝,为构建人类卫生健康 | | 专有名词表 | 113 | | | | 共同体贡献中国力量 | 18 | 读者反馈表 | 114 | | | | | 01. | | 02. | | 03. | | 责任管治 | | 合规运营 | | 产品责任 | | | 公司治理 | 27 | 责任采购 | 37 | 产品质量 | 47 | | 风控内审 | 31 | 伦理保障 | 41 | 研发创新 | 56 | | 商业道德 | 34 | 信息安全 | 45 | 客户服务 | 61 | | | 04. | | 05. | | 06. | | 员工发展 | | 践行低碳 | | ...

康希诺生物股份公司审计委员会 对 2023 年度会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号） 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》和康希诺 生物股份公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作细 则》等规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履 职。现将董事会审计委员会对 2023 年度会计师事务所履行监督职责的情况汇报 如下： 一、聘任会计师事务所履行的程序 1、2023 年 3 月 22 日，公司第二届董事会审计委员会召开第十二次会议， 同意公司聘请德勤华永会计师事务所（特殊普通合伙）（以下简称"德勤华永"） 为 2023 年境内审计机构及内部控制审计机构，德勤·关黄陈方会计师行（以下 简称""德勤香港"）为 2023 年境外审计机构，并同意将该议案提交公司董事会审 议。 2、公司独立董事对聘请境内外审计机构及内部控制审计机构事项进行了事 前审核，发表了事前认可意见： 公司全体独立董事认为公司续聘德勤华永 ...